|Bid||40.00 x 4000|
|Ask||41.41 x 1000|
|Day's Range||40.15 - 40.66|
|52 Week Range||35.78 - 42.36|
|Beta (3Y Monthly)||0.55|
|PE Ratio (TTM)||40.88|
|Earnings Date||Feb 1, 2017 - Feb 6, 2017|
|Forward Dividend & Yield||2.39 (5.84%)|
|1y Target Est||43.84|
Rolls-Royce said it wouldn’t comment beyond noting the news. The SFO launched its probe into GlaxoSmithKline in 2014, looking at the pharmaceutical giant’s operations in a number of countries, including China. Last year, the SFO had requested additional information on the company’s use of third-party advisers.
The UK's Serious Fraud Office (SFO) has abandoned two of its largest and longest investigations, into alleged bribery at aero engine maker Rolls-Royce and drugs maker GlaxoSmithKline, in a move described by one lawyer as "extraordinary". The decision, which comes under SFO Director Lisa Osofsky who took the helm last August pledging to review the agency's caseload, weed out weaker cases and propel others forward, underlines the difficulties of prosecuting senior executives. Rolls-Royce paid almost 500 million pounds ($650 million) under a Deferred Prosecution Agreement (DPA) with the SFO in 2017, drawing a line under a four-year investigation into allegations of criminal conduct spanning three decades, at least seven jurisdictions and three of the company's business sectors.
Merck's (MRK) sBLA looking for approval of Keytruda monotherapy for the third-line treatment of small cell lung cancer, a difficult-to-treat cancer, gets FDA's priority review.
Novo Nordisk (NVO) clinches the FDA approval for its biologics license application in favor of Esperoct to treat adults and children suffering haemophilia A.
Holdings Inc., which makes painkiller Zohydro and other medications, has filed for bankruptcy protection after drug sales to consumers fell below expectations. It blamed a revenue drop partly on fresh competition with generic versions of its migraine treatment Treximet. In documents filed in U.S. Bankruptcy Court in Wilmington, Del., company officials said they already have a $76 million offer from affiliates of Highbridge Capital Management LLC, which offered to pay cash and forgive some of its debt.
Bayer (BAYRY) obtains full exclusive licensing rights for the global development and commercialization of Vitrakvi (larotrectinib) and BAY 2731954 (LOXO-195) from Loxo.
Is Teva Pharmaceutical an Attractive Pick This February?Stock price movementsOn February 15, Teva Pharmaceutical (TEVA) closed at $17.98, 4.05% higher than its previous closing price, 23.24% higher than its 52-week low of $14.59, and 30.74% lower
Announcement: Moody's announces completion of a periodic review of ratings of Innoviva, Inc. New York, February 15, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Innoviva, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)Growth drivers On its fourth-quarter earnings conference call, GlaxoSmithKline (GSK) highlighted the prioritization of R&D (research and development)
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)Dividend projectionsMerck & Co. (MRK) and GlaxoSmithKline (GSK) reported dividends per share of $1.99 and $2.08, respectively, in 2018.Analysts expect
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)Expenses guidance for 2019 On its fourth-quarter earnings conference call, Merck & Co. (MRK) guided for a low- to mid-single-digit YoY (year-over-year) rise
Johnson & Johnson (JNJ) entered into a definitive agreement to acquire Auris Health, Inc., a developer of robotic technologies focused on lung cancer, for approximately $3.4 billion in cash.
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)EPS guidance for 2019 On its fourth-quarter earnings conference call, Merck & Co. (MRK) guided for non-GAAP (generally accepted accounting principles) EPS
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)Revenue guidance for 2019 On its fourth-quarter earnings conference call, Merck & Co. (MRK) guided for revenue of $43.2 billion–$44.7 billion, a YoY
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?Share price movements On February 11, Merck & Co. (MRK) closed at $76.71, 1.04% lower than its previous closing price, 45.20% higher than its 52-week low of $52.83, and 4.34% lower
AstraZeneca (AZN) beats earnings and sales estimates in the fourth quarter and provides encouraging outlook for 2019. Shares up.